Letter

Shared scheme for assessing drugs for multiple sclerosis :Dealing with uncertainties about cost effectiveness of treatments is difficult problem

BMJ 2003; 326 doi: 10.1136/bmj.326.7400.1212-a (Published 29 May 2003)
Cite this as: BMJ 2003;326:1212.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. David Chadwick, professor of neurology (dwc@liv.ac.uk),
  2. Richard Gray, professor of statistics
  1. Walton Centre for Neurology and Neurosurgery, University of Liverpool, Liverpool L9 7LJ
  2. Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT

    EDITOR—Sudlow and Counsell argue for a trial comparing disease modifying treatments with azathioprine, and placebo as an alternative to the risk sharing scheme, which they believe to be scientifically unsound.1 As independent scientific advisers to the scheme we would like to correct some inaccuracies.

    Firstly, patients who have already been prescribed disease modifying treatments will not contribute to the main analyses of cost effectiveness. …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular